*Some Market data delayed by 15 mins.

Coherus BioSciences, Inc.

Symbol: CHRS (NASDAQ)
1.67 ▲ (3.73%) 0.060

Company Description:
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Key Stats
  • Today's Open: $1.65
  • Today's High: $1.73
  • Today's Low: $1.58
  • Today's Volume: 1.45M
  • Yesterday Close: $1.61
  • Yesterday High: $1.65
  • Yesterday Low: $1.475
  • Yesterday Volume: 1.59M
  • Last Min Volume: 200
  • Last Min High: $1.67
  • Last Min Low: $1.67
  • Last Min VWAP: $1.67
Company Profile
  • Name: Coherus BioSciences, Inc.
  • Website: https://www.coherus.com
  • Listed Date: 2014-11-06
  • Location: REDWOOD CITY, CA
  • Market Status: Active
  • CIK Number: 0001512762
  • SIC Code: 2836
  • SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • Market Cap: $190.44M
  • Round Lot: 100
  • Outstanding Shares: 114.73M
  • Asset Type: CS
RECENT FILINGS FOR CHRS
Filing DateFiling TypeFormat
2024-07-028-KView
2024-06-278-KView
2024-06-054View
2024-06-053View
2024-06-054View
2024-06-054View
2024-06-054View
2024-06-054View
2024-06-054View
2024-06-054View
2024-06-054View
2024-06-054View
2024-06-058-KView
2024-06-048-KView
2024-05-22SC 13G/AView
2024-05-218-K/AView
2024-05-13DEFA14AView
2024-05-0910-QView
2024-05-098-KView
2024-05-098-KView
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.